CON-VINCE Study – Behind the scenes (PART I)
09 June 2020
CON-VINCE as a role model for translational research collaboration in Luxembourg (PART I)
IBBL a as key integrator
On 8th April, the CON-VINCE study was officially launched, with the aim to assess the spread dynamics of the COVID-19 disease among the Luxembourgish population.
Only 2 days later, all necessary material for starting up was already available (many thanks to LIH Buildings & Equipments team), coordination between the numerous partners around a single workflow was optimal, and all security conditions (many thanks to LIH Compliance Office team) were met to start the study. A real feat!
Within just 10 days, 1862 people were recruited, biosampled and tested!
Throwback to a logistical, technical and human challenge, which was met thanks to the incredible collaboration of all the IBBL, LIH, LCSB, CHL staff and partner laboratories from BioNext, Ketterthill and Laboratoires Réunis.
Such an ant work was carried out by the IBBL Biorepository team and various volunteers. IBBL acted as a leader in the biosampling task force together with other stakeholders. Recruitment, as well as the coordination of collection partners, was a key point.
A huge thanks to IBBL Biorepository and Biorefinery teams who gave their all without counting the hours, so that everything could work smoothly!
As a result, in only 10 days, 3,370 kits for the collection of blood and pharyngeal samples and 1,650 kits for the collection of stool samples were distributed to the country’s partner laboratories at an unprecedented cadence.
Blood and naso-pharyngeal samples from study participants collected at the 3 partner laboratories (Ketterthill, BioneXt and Laboratoires Réunis) and including home visits, were and transported (twice a day, sometimes more) to IBBL Biorepository by Biologistics (important role in the quick start of this study).
They were then dispatched as follows:
- naso-pharyngeal swabs to the LNS for SARS-CoV2 virus detection by amplifying ribonucleic acid (RNA) before returning to IBBL to be stored
- blood samples to Biorefinery team for “processing”
- transfer of forms for data encoding (cf step 5 photo bottom left)
The “Processing” (manual and automated) consists in preparing different biological fractions for storage (serum or plasma for example). Training in the management of serum and plasma, naso-pharyngeal swabs, extracted RNA and stool aliquoting was necessary for volunteers and was organized in record time. The treated samples could then be redistributed to the LNS and LIH for analysis.
Daily processing of samples from 39 to 349 patients per day which, at the end of the first wave, allowed the storage of more than 37,000 aliquots, a large part of which was already used for research purposes within CON-VINCE and beyond.
A proper data collection was key to carry out this study.
Proper data encoding of the paper forms received with the samples was key to carry out this study and was done by our clinical team partners at CHL and UL. To link the participants to their samples through the paper forms and their questionnaire answers, the data team of the LCSB Computing Platform worked day and night from the beginning of the study to set up the complex and secure data infrastructure. This allows the information to be properly stored and synchronized, and updated daily with the results of the tests for the virus.
All those activities are still ongoing with the same team spirit! Thumbs up to all teams working on this great project!
“This unprecedented study, due to its complexity and urgency, was like the outline of a music score, which each one of us fed with his musical orientations. Conductors agreed, musicians practiced, others discovered their instruments, adapted, trained and above all helped each other, all in record time. The ultimate goal is to play this collaborative score in unison. Objective achieved: The melody is there! “Katy Beaumont, Head of BioRepository at IBBL and COVID Fighter.
Superimmunity: A defence mechanism against COVID-19?Two years after the pandemic outbreak, researchers and scientists continue to look at the immune system’s defence mechanisms against the…
The why behind mild COVID-19From the start of the COVID-19 pandemic, the majority of published studies have focused on severe COVID-19 patients in order…
In conversation with our young researchers: Abir ElbéjiHow to better follow COVID-19-related symptoms thanks to new digital biomarkers and tools and how to improve Long Covid patients’…
Shedding light on COVID-19 – Presentation of CoVaLuxDespite the worldwide COVID-19 pandemic entering its third year, open questions pertaining to the occurrence of new variants, ensuing new…
Europe must come together to confront OmicronOmicron. The SARS-CoV-2 Omicron variant is spreading rapidly in Europe, even in countries with high levels of vaccination, including those…
What are the benefits, costs and feasibility of a low incidence COVID-19 strategyA low incidence strategy. Lifting some non-pharmaceutical interventions means living with a relatively high incidence of cases. Such a high…
Survey reveals 87% of Luxembourg vaccinees are eager to get a booster jab or already got itHow many vaccinated people want to get a booster jab? How many parents have had their children vaccinated? A recent representative survey…
COVID-19: Mothers absorbed the higher burden for childcareDid the traditional division of roles within households just carry over through the pandemic? Or, did it make it worse…